Phosphodiesterase Enzyme (PDE) Inhibitors Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies. The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors has made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms has and will result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors. Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/172 Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is anticipated to benefit the drug in long term and contribute to the increasing revenues of PDE inhibitors market. • Researchers from the John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension (2017). • Besides, PDE-5 inhibitor sildenafil accidently developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit heart attack patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death of hospitalization for heart failure in men who have had one heart attack in their lifetime. • Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa the first non-steroidal topical monotherapy for skin disorder. Report includes chapters which deeply display the following deliverable about industry : • Phosphodiesterase Enzyme Inhibitors Market Research Objective and Assumption • Phosphodiesterase Enzyme Inhibitors Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Phosphodiesterase Enzyme Inhibitors Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Phosphodiesterase Enzyme Inhibitors Market, By Regions • Phosphodiesterase Enzyme Inhibitors Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Phosphodiesterase Enzyme Inhibitors Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Phosphodiesterase Enzyme Inhibitors Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Phosphodiesterase Enzyme Inhibitors Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key Players Some of the key players operating in the global phosphodiesterase enzyme inhibitors market include Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals. Market Taxonomy The global phosphodiesterase enzyme inhibitors market is therefore analyzed based on the drug class and application as follows: • Drug Class - Selective PDE inhibitors • PDE-1 • PDE-2 • PDE-3 • PDE-4 • PDE-5 • Others - Non-selective PDE inhibitors • Application • Cardiovascular Disease • Respiratory Disease • Erectile Dysfunction • Pulmonary Hypertension • Benign Prostate Hyperplasia • Others Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/phosphodiesterase-enzyme-inhibitors-market-172 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers.
© Copyright 2024 Paperzz
